Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses integrating immune checkpoint inhibitors, improving efficacy, and reducing toxicity when treating blood cancers.
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as a possible treatment modality.
James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.
Mary L. Disis, MD, of the University of Washington, discusses innate and adaptive immune system cells, T cells as key to mediating antitumor immunity, and the mechanisms by which cancer evades the immune system.
Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.
Aaron Goodman, MD, of the University of California, San Diego School of Medicine, discusses an analysis of more than 100,000 patients with cancer for CD274 (PD-L1) amplification and the implications for treatment with immune checkpoint blockade (Abstract 47).
